Amarin reported $3K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amarin USD 3K 3K Dec/2024
AstraZeneca 303M 126M Jun/2025
DBV Technologies 461K 323.71K Mar/2025
GlaxoSmithKline 184M 22M Jun/2025
Halozyme Therapeutics USD 4.39M 131K Jun/2025
Ionis Pharmaceuticals USD 19M 0 Jun/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 289M 19M Jun/2025